Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, non-interventional, observational, post-marketing surveillance safety and efficacy study of biosimilar insulin glargine in type 1 or type 2 diabetes mellitus in Japanese patients

Next Previous
Trial Profile

A prospective, non-interventional, observational, post-marketing surveillance safety and efficacy study of biosimilar insulin glargine in type 1 or type 2 diabetes mellitus in Japanese patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly Japan; Nippon Boehringer Ingelheim

Most Recent Events

  • 21 Jan 2020 New trial record
  • 06 Dec 2019 Results assessing first long term safety and efficacy of biosimilar insulin glargine in type 1 or type 2 diabetes mellitus patients, presented at the 2019 Congress of the International Diabetes Federation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top